Seqirus announces U.S. FDA approval of its first-ever adjuvanted, cell-based pandemic influenza A (H5N1) vaccine

3 February 2020 - Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. FDA ...

Read more →

Novavax granted fast track designation for NanoFlu in older adults

15 January 2020 - Novavax today announced that the U.S. FDA has granted fast track designation for NanoFlu, its recombinant quadrivalent ...

Read more →

Trump to order drive for improved flu vaccine

16 July 2019 - President Donald Trump is readying an executive order that would direct HHS to overhaul the development ...

Read more →

Seqirus receives FDA approval of Afluria Quadrivalent (influenza vaccine) for people six months of age and older in the U.S.

17 October 2018 - Seqirus today announced the U.S. FDA has approved Afluria Quadrivalent (influenza vaccine) for use in people ...

Read more →

Statement from FDA Commissioner on FDA’s ongoing efforts to help improve effectiveness of influenza vaccines

26 February 2018 - The current influenza season has been especially difficult, causing widespread illness that has affected all fifty ...

Read more →

Seqirus receives FDA approval for Afluria Quadrivalent (influenza vaccine) for people 18 years of age and older

29 August 2016 - Seqirus is shipping trivalent and quadrivalent formulations of Afluria in the 2016-2017 influenza season. ...

Read more →

FDA approves CSL's Flucelvax quadrivalent influenza vaccine

24 May 2016 - CSL today announced that the US FDA has approved Seqirus’ Flucelvax Quadrivalent (Influenza Vaccine), the first four-strain, ...

Read more →